Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hamberg

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Cancer Chemotherapy and Pharmacology|December 24, 2014
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedulesP Hamberg, R H J Mathijssen, P de Bruijn, et al.
British Journal of Cancer|December 25, 2013
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyP Hamberg, M J Boers-Sonderen, W T A van der Graaf, et al.
Clinical and Translational Science|April 4, 2017
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronideS Bins, L van Doorn, M A Phelps, et al.
Clinical Genitourinary Cancer|January 21, 2024
Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel MonotherapyK van der Zande, R D Tutuhatunewa-Louhanepessy, P Hamberg, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2015
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancerR J van Soest, A J M Nieuweboer, E S de Morrée, et al.
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Clinical Pharmacokinetics|January 19, 2026
The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1)Amy Rieborn, Niels A D Guchelaar, Teun van Gelder, et al.
The Pharmacogenomics Journal|September 9, 2015
Role of genetic variation in docetaxel-induced neutropenia and pharmacokineticsA J M Nieuweboer, M Smid, A-J M de Graan, et al.
Frontiers in Oncology|July 12, 2021
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer PatientsI E de Kruijff, A M Sieuwerts, N Beije, et al.
International Journal of Clinical Oncology|December 6, 2017
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The NetherlandsJohannes J M Kwakman, G Vink, J H Vestjens, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|December 24, 2014
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedulesP Hamberg, R H J Mathijssen, P de Bruijn, et al.
British Journal of Cancer|December 25, 2013
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyP Hamberg, M J Boers-Sonderen, W T A van der Graaf, et al.
Clinical and Translational Science|April 4, 2017
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronideS Bins, L van Doorn, M A Phelps, et al.
Clinical Genitourinary Cancer|January 21, 2024
Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel MonotherapyK van der Zande, R D Tutuhatunewa-Louhanepessy, P Hamberg, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2015
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancerR J van Soest, A J M Nieuweboer, E S de Morrée, et al.
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Clinical Pharmacokinetics|January 19, 2026
The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1)Amy Rieborn, Niels A D Guchelaar, Teun van Gelder, et al.
The Pharmacogenomics Journal|September 9, 2015
Role of genetic variation in docetaxel-induced neutropenia and pharmacokineticsA J M Nieuweboer, M Smid, A-J M de Graan, et al.
Frontiers in Oncology|July 12, 2021
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer PatientsI E de Kruijff, A M Sieuwerts, N Beije, et al.
International Journal of Clinical Oncology|December 6, 2017
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The NetherlandsJohannes J M Kwakman, G Vink, J H Vestjens, et al.
Pageof 6